HYPERSENSITIVITY OF LYMPHOBLASTOID LINES DERIVED FROM ATAXIA-TELANGIECTASIA PATIENTS TO THE INDUCTION OF CHROMOSOMAL-ABERRATIONS BY ETOPOSIDE (VP-16)

被引：18

作者：

CAPOROSSI, D

PORFIRIO, B

NICOLETTI, B

PALITTI, F

DEGRASSI, F

DESALVIA, R

TANZARELLA, C

机构：

[1] UNIV FLORENCE,DEPT CLIN PHYSIOPATHOL,I-50121 FLORENCE,ITALY

[2] LA TUSCIA UNIV,DEPT AGROBIOL,VITERBO,ITALY

[3] CNR,CTR GENET EVOLUZIONIST,ROME,ITALY

[4] UNIV ROMA LA SAPIENZA,DEPT GENET & MOLEC BIOL,I-00185 ROME,ITALY

来源：

MUTATION RESEARCH | 1993年 / 290卷 / 02期

关键词：

ATAXIA TELANGIECTASIA; VP-16; CHROMOSOMAL ABERRATIONS;

D O I：

10.1016/0027-5107(93)90167-E

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Mammalian DNA topoisomerase II represents the cellular target of many antitumor drugs, such as epipodophyllotoxin VP-16 (etoposide). The mechanism by which VP-16 exerts its cytotoxic and antineoplastic actions has not yet been firmly established, although the unique correlation between sensitivity to ionizing radiation and to topoisomerase II inhibitors suggest the involvement of DNA double-strand breaks. In the present study we analyzed the chromosomal sensitivity of lymphoblastoid cell lines derived from ataxia telangiectasia (AT) patients to low concentrations of the drug. Our results indicate that AT derived cells are hypersensitive to the clastogenic activity of VP-16 either when the drug is present for the whole duration of the cell cycle or specifically in the G2 phase, confirming that the induction of DNA double strand breaks, to which AT cells seem typically sensitive, could have an important role in the biological activity of VP-16.

引用

页码：265 / 272

页数：8

共 34 条

[1]

Andersson, Kihlman, The production of chromosomal alterations in human lymphocytes by drugs known to interfere with the activity of DNA topoisomerase II. I. m-AMSA, Carcinogenesis, 10, pp. 123-130, (1989)

[2]

Antonelli, Elli, Marcucci, Bosi, Kobal, Petrinelli, Human cells (normal and ataxia telangiectasia) transfected with pR plasmid are hypersensitive to DNA strand-breaking agents, Mutation Res., 255, pp. 11-18, (1991)

[3]

Backer, Allen, Harrington-Brock, Campbell], DeMarini, Doerr, Howard, Kligerman, Moore, Genotoxicity of inhibitors of DNA topoisomerases I (camptothecin) and II (m-AMSA) in vivo and in vitro, Mutagenesis, 5, pp. 541-547, (1990)

[4]

Blocher, Sigut, Hannan, Fibroblasts from ataxia telangiectasia (AT) and AT heterozygotes show enhanced level of residual DNA double-strand breaks after low dose-rate γ-irradiation as assayed by pulsed field gel electrophoresis, Int. J. Radiat. Biol., 60, pp. 791-802, (1991)

[5]

Bridges, Harnden, Ataxia-Telangiectasia — A Cellular and Molecular Link between Cancer, Neuropathology and Immune Deficiency, (1982)

[6]

Bryant, Enzymatic restriction of mammalian cell DNA using Pvu II and Bam HI: evidence for the double strand break origin of chromosomal aberrations, Int. J. Radiat. Biol., 46, pp. 57-65, (1984)

[7]

Caldecott, Banks, Jeggo, DNA double-strand break repair pathways and cellular tolerance to inhibitors of topoisomerase II, Cancer Res., 50, pp. 5778-5783, (1990)

[8]

Chen, Yang, Rowe, Halligan, Tewey, Liu, Non-intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II, J. Biol. Chem., 259, pp. 13565-13566, (1984)

[9]

Cohen, Sagi, Ben-Zur, Schaap, Voss, Kohn, Ben-Bassat, Ataxia telangiectasia: chromosomal stability in continous lymphoblastoid cell lines, Cytogenet. Cell Genet., 23, pp. 44-52, (1979)

[10]

Cunningham, Francis, Holland, Pirollo, Chang, Aberrant DNA topoisomerase II activity, radioresistance and inherited susceptibility to cancer, Br. J. Cancer, 63, pp. 29-36, (1991)

← 1 2 3 4 →